A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I
Public ClinicalTrials.gov record NCT01142700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Based on 12-week on-treatment data, at least 1 dose of BMS-824393 can be identified which is safe, well tolerated, and has sufficient antiviral activity to progress to late stage clinical trials when combined with pegIFNα/RBV for treatment of chronically infected hepatitis C virus genotype 1 treatment-naive subjects.
Study identification
- NCT ID
- NCT01142700
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2010 (Type not available)
- Primary completion
- Dec 2010 (Estimated)
- Completion
- Dec 2010 (Estimated)
- Last update posted
- Mar 15, 2011
2010
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Coronado | California | 92118 | — |
| Research And Education, Inc. | San Diego | California | 92105 | — |
| Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| Bach And Godofsky Infectious Diseases | Bradenton | Florida | 34209 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Vita Medical Center & Research Solutions, Inc. | Tamarac | Florida | 33319 | — |
| Gastrointestinal Specialists Of Georgia Pc | Mareitta | Georgia | 30060 | — |
| Maryland Digestive Disease Research | Laurel | Maryland | 20707 | — |
| Local Institution | Philadelphia | Pennsylvania | 19141 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Liver Institute Of Virginia Bon Secours Health System | Newport News | Virginia | 23602 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01142700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2011 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01142700 live on ClinicalTrials.gov.